LINZESS Sales Rise as Guidance IncreasesLINZESS generated $282.3 million in U.S. net sales during the second quarter, up 14% from a year earlier. She said Ironwood expects reduced quarterly variability in net sales during 2026 because net prices are more consistent across channels than they were last year. The company expects LINZESS demand to build in the second half, with the fourth quarter projected to produce the highest net sales of the year. McCourt said the company expects gross leverage to be below one times by year-end. About Ironwood Pharmaceuticals (NASDAQ:IRWD)Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders.